<DOC>
	<DOCNO>NCT00118963</DOCNO>
	<brief_summary>Aim : The United Kingdom Prospective Diabetes Study ( UKPDS ) show reduction cardiovascular event obese patient type-2-diabetes treat metformin compare hypoglycaemic treatment difference glycemic control treatment . Non-obese patient type-2-diabetes usually treat insulin-secretagogues insulin diet fail . Since non-obese patient type-2-diabetes also carry high risk cardiovascular event , use metformin sub-group patient might beneficial . Moreover , insulin-treatment initiated ongoing oral hypoglycaemic agent ( OHA ) often continue , non-obese patient type-2 diabetes little evidence exist choose optimal class OHA combine insulin . The aim project therefore investigate effect metformin vs. insulin-secretagogue ( repaglinide ) combination insulin glycemic control non-glycemic cardiovascular risk-factors non-obese patient type-2-diabetes , uncontrolled diet alone . Methodology : Single-center , double-blind , double-dummy , randomize , parallel study involve 100 non-obese ( BMI 27 kg/m2 low ) patient type-2-diabetes investigating effect treatment metformin vs. repaglinide combination biphasic insulin ( Insulin-aspart 30/70 , BIAsp30 ) period 12 month .</brief_summary>
	<brief_title>Effect Repaglinide Versus Metformin Treatment Non-Obese Patients With Type-2-Diabetes</brief_title>
	<detailed_description>After four month run-in repaglinide plus metformin combination-therapy , patient HemoglobinA1c â‰¥6.5 % randomize ( baseline=0 month ) repaglinide 2 mg thrice-daily metformin 1g twice-daily , combination BIAsp30 ( 30 % insulin-aspart ; 70 % protaminated insulin-aspart ) ( 6U once-daily , pre-dinner ) 12 month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Nonobese patient ( BMI &lt; 27 kg/m2 ) Type 2 diabetes Age 40 year old HbA1c = 6.5 % high baseline . No known contraindication either studydrugs ( know allergy studydrugs ; heart , liver kidneyfailure ) Pregnancy Other serious physical mental illness lifeshortening prognosis . Drug alcohol abuse . Weightloss 5 kg last 6 month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>